Accelerate the development and adoption of data-driven innovation and standards to increase the speed and resilience of biopharmaceutical manufacturing.
Data-driven technologies optimize the productivity of biopharmaceutical manufacturing and accelerate the delivery of high-quality medicines to patients.
“Big Data” encompasses advanced uses of data and data-driven technologies that could transform the manufacturing of biopharmaceuticals and better meet the needs of biomanufacturers, suppliers, regulators, and patients. Benefits to and impacts on the industry include:
The work of the program is organized around workstreams—topical focus areas—and cross-cutting key capabilities themes.
Support uniform collection and exchange of Big Data to harness its value.
Quickly interpret data patterns and generate insights across multiple applications
Facilitate the process of storing and merging data to collaborate and share information more easily
NIIMBL Big Data Program Biopharmaceutical Manufacturing Ontology
Forecast and mitigate potential risks to maintain quality and efficiency in the biopharmaceutical manufacturing process
Cell Culture Glycosylation Multi-scale Mechanistic Modeling (Phase 1)
Protein A Chromatography Multi-scale Mechanistic Modeling (Phase 1)
Cell Culture Glycosylation Multi-scale Data Driven Mechanistic Modeling (Phase 2)
Protein A Chromatography Multi-scale Data Driven/Mechanistic Modeling (Phase 2)
Improve quality management for pharmaceutical manufacturing and distribution
Convened NIIMBL Big Data Program Re-envision Workshop to develop a roadmap for the future of the Program
Funded projects to advance standardization and contextualization, real-time control of critical quality attributes (CQAs), multivariate sensors and analytics, rich data generation, and bioprocess modeling and simulation
Convened workshops to identify needs and opportunities, define priority workstreams, and plan first 2 years of the program
Technical Activities Committee (TAC) prioritized Big Data as an area of focus; industry leaders and subject matter experts met at 2019 National Meeting to begin to define a program
AstraZeneca
Boehringer Ingelheim
Bristol-Myers Squibb
Cytiva
Federal Stakeholder: National Institute of Standards and Technology
Genentech, Inc.
GlaxoSmithKline, LLC
Merck Sharp & Dohme LLC
MilliporeSigma/EMD Serono
NIIMBL
Pfizer, Inc.
Sanofi
Takeda Pharmaceuticals
Access more program information, including:
Learn more about how being a member of NIIMBL can grant you and your company access to NIIMBL-led programs and other collaboration opportunities.